Orthopediatrics (NASDAQ:KIDS) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Orthopediatrics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 14th. ValuEngine upgraded shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $31.33.

KIDS stock traded down $0.83 during trading on Thursday, hitting $28.88. The company had a trading volume of 28,673 shares, compared to its average volume of 44,486. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.67 and a quick ratio of 3.23. Orthopediatrics has a 12 month low of $14.00 and a 12 month high of $39.81. The stock has a market capitalization of $380.76 million and a PE ratio of -5.07.

Orthopediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Wednesday, October 31st. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Orthopediatrics had a negative return on equity of 65.26% and a negative net margin of 55.97%. The company had revenue of $15.82 million during the quarter, compared to the consensus estimate of $15.19 million. During the same quarter last year, the firm earned ($1.70) EPS. The business’s revenue for the quarter was up 27.8% on a year-over-year basis. As a group, equities analysts expect that Orthopediatrics will post -0.95 earnings per share for the current fiscal year.

In other Orthopediatrics news, General Counsel Daniel J. Gerritzen sold 9,525 shares of Orthopediatrics stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $33.73, for a total transaction of $321,278.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Unger sold 1,000 shares of Orthopediatrics stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $33.22, for a total transaction of $33,220.00. The disclosure for this sale can be found here. Insiders own 46.10% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sei Investments Co. acquired a new stake in Orthopediatrics during the 2nd quarter worth $126,000. Millennium Management LLC acquired a new stake in Orthopediatrics during the 1st quarter worth $172,000. Rhumbline Advisers acquired a new stake in Orthopediatrics during the 3rd quarter worth $207,000. Regal Investment Advisors LLC acquired a new stake in Orthopediatrics during the 3rd quarter worth $246,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in Orthopediatrics during the 3rd quarter worth $248,000. 40.22% of the stock is owned by hedge funds and other institutional investors.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

See Also: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.